BMO Capital Markets reissued their outperform rating on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a research note published on Thursday. The firm currently has a $84.00 price objective on the stock.

NBIX has been the topic of several other reports. Piper Jaffray Companies set a $68.00 target price on Neurocrine Biosciences and gave the stock a buy rating in a report on Thursday, August 24th. BidaskClub raised Neurocrine Biosciences from a hold rating to a buy rating in a report on Wednesday, August 9th. Needham & Company LLC reaffirmed a buy rating and set a $58.00 target price on shares of Neurocrine Biosciences in a report on Sunday, September 17th. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $70.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 7th. Finally, ValuEngine raised Neurocrine Biosciences from a sell rating to a hold rating in a report on Friday, September 1st. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $68.44.

Neurocrine Biosciences (NASDAQ NBIX) traded down 0.18% during midday trading on Thursday, reaching $62.44. The company had a trading volume of 583,747 shares. The company’s market capitalization is $5.51 billion. The stock has a 50-day moving average price of $57.19 and a 200 day moving average price of $50.50. Neurocrine Biosciences has a 12-month low of $37.35 and a 12-month high of $63.77.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. Equities analysts forecast that Neurocrine Biosciences will post ($2.45) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/08/bmo-capital-markets-reaffirms-outperform-rating-for-neurocrine-biosciences-inc-nbix.html.

In related news, insider Haig P. Bozigian sold 26,250 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $1,575,000.00. Following the completion of the sale, the insider now directly owns 144,601 shares of the company’s stock, valued at approximately $8,676,060. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $436,700.00. Following the completion of the sale, the insider now directly owns 57,707 shares of the company’s stock, valued at $2,885,350. The disclosure for this sale can be found here. Insiders sold a total of 132,580 shares of company stock valued at $7,440,850 over the last ninety days. 4.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas increased its position in Neurocrine Biosciences by 0.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock valued at $320,000 after buying an additional 57 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares in the last quarter. Utah Retirement Systems increased its position in Neurocrine Biosciences by 1.9% in the 2nd quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock valued at $736,000 after buying an additional 300 shares in the last quarter. Schroder Investment Management Group increased its position in Neurocrine Biosciences by 1.7% in the 1st quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock valued at $856,000 after buying an additional 335 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its position in Neurocrine Biosciences by 5.6% in the 1st quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock valued at $626,000 after buying an additional 763 shares in the last quarter.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.